Arbutus Biopharma
ABUS
ABUS
53 hedge funds and large institutions have $207M invested in Arbutus Biopharma in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
7.04% less ownership
Funds ownership: 67.03% → 60% (-7%)
17% less call options, than puts
Call options by funds: $141K | Put options by funds: $169K
Holders
53
Holding in Top 10
2
Calls
$141K
Puts
$169K
Top Buyers
| 1 | +$1.39M | |
| 2 | +$775K | |
| 3 | +$585K | |
| 4 |
RI
RTW Investments
New York
|
+$350K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$325K |
Top Sellers
| 1 | -$26.6M | |
| 2 | -$1.28M | |
| 3 | -$1.1M | |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$895K |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$780K |